CORRIGENDUM

Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy

C Berlin, DJ Kowalewski, H Schuster, N Mirza, S Walz, M Handel, B Schmid-Horch, HR Salih, L Kanz, H-G Rammensee, S Stevanović and JS Stickel

Leukemia (2016) 30, 1003–1004; doi:10.1038/leu.2016.1

Correction to: *Leukemia* (2015) 29, 647–659; doi:10.1038/leu.2014.233; published online 29 August 2014

Following the publication of this article, the authors noted that there were errors in Figure 4a and c. The correct figure appears below:

Figure 4. Functional characterization of HLA class I AML LiTAPs. **(a)** IFN- γ ELISPOT assay of AML patient PBMCs after stimulation with two different A*03-restricted AML LiTAP pools (P₁^I and P₂^I). PHA served as a positive control, and stimulation with HIVGAG_{18–26} A*03 peptide as a negative control. For P₁^I and P₂^I a significant IFN- γ production was observed. **(b)** Intracellular staining for IFN- γ and TNF- α of P₁^I- and P₂^I-stimulated AML patient PBMCs (same as in **(a)**). Phorbol myristate acetate (PMA)/ionomycin served as a positive control, and HIV GAG_{18–26} A*03 peptide as a negative control. **(c)** Cross-checking IFN- γ ELISPOT assay of healthy donor PBMCs after stimulation with A*03-restricted AML LiTAP pools P₁^I and P₂^I revealed no significant IFN- γ production.